Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates
- PMID: 16489038
- DOI: 10.1158/0008-5472.CAN-05-2883
Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates
Abstract
Metastatic renal cell carcinoma (RCC) is an aggressive disease refractory to most existing therapeutic modalities. Identifying new markers for disease progression and drug targets for RCC will benefit this unmet medical need. We report a subset of clear cell and papillary cell RCC aberrantly expressing the lymphocyte activation marker CD70, a member of the tumor necrosis factor superfamily. Importantly, CD70 expression was found to be maintained at the metastatic sites of RCC. Anti-CD70 antibody-drug conjugates (ADC) consisting of auristatin phenylalanine phenylenediamine (AFP) or monomethyl auristatin phenylalanine (MMAF), two novel derivatives of the anti-tubulin agent auristatin, mediated potent antigen-dependent cytotoxicity in CD70-expressing RCC cells. Cytotoxic activity of these anti-CD70 ADCs was associated with their internalization and subcellular trafficking through the endosomal-lysosomal pathway, disruption of cellular microtubule network, and G2-M phase cell cycle arrest. The efficiency of drug delivery using anti-CD70 as vehicle was illustrated by the much enhanced cytotoxicity of antibody-conjugated MMAF compared with free MMAF. Hence, ADCs targeted to CD70 can selectively recognize RCC, internalize, and reach the appropriate subcellular compartment(s) for drug release and tumor cell killing. In vitro cytotoxicity of these ADCs was confirmed in xenograft models using RCC cell lines. Our findings provide evidence that CD70 is an attractive target for antibody-based therapeutics against metastatic RCC and suggest that anti-CD70 ADCs can provide a new treatment approach for advanced RCC patients who currently have no chemotherapeutic options.
Similar articles
-
Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker.Clin Cancer Res. 2008 Oct 1;14(19):6171-80. doi: 10.1158/1078-0432.CCR-08-0916. Epub 2008 Sep 22. Clin Cancer Res. 2008. PMID: 18809969
-
AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.Clin Cancer Res. 2016 Apr 15;22(8):1989-99. doi: 10.1158/1078-0432.CCR-15-1542. Epub 2015 Nov 20. Clin Cancer Res. 2016. PMID: 26589436
-
Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.Oncotarget. 2015 Oct 20;6(32):33046-64. doi: 10.18632/oncotarget.5422. Oncotarget. 2015. PMID: 26426994 Free PMC article.
-
CD70 as a therapeutic target in human malignancies.Expert Opin Ther Targets. 2008 Mar;12(3):341-51. doi: 10.1517/14728222.12.3.341. Expert Opin Ther Targets. 2008. PMID: 18269343 Review.
-
Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies.Pharmacol Ther. 2017 Feb;170:8-13. doi: 10.1016/j.pharmthera.2016.10.007. Epub 2016 Oct 18. Pharmacol Ther. 2017. PMID: 27765652 Review.
Cited by
-
Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy.Cancers (Basel). 2024 Mar 19;16(6):1209. doi: 10.3390/cancers16061209. Cancers (Basel). 2024. PMID: 38539542 Free PMC article. Review.
-
Simultaneous Expression of CD70 and POSTN in Cancer-Associated Fibroblasts Predicts Worse Survival of Colorectal Cancer Patients.Int J Mol Sci. 2024 Feb 22;25(5):2537. doi: 10.3390/ijms25052537. Int J Mol Sci. 2024. PMID: 38473788 Free PMC article.
-
Immunoinformatics Approach to Design a Chimeric CD70-Peptide Vaccine against Renal Cell Carcinoma.J Immunol Res. 2024 Jan 27;2024:2875635. doi: 10.1155/2024/2875635. eCollection 2024. J Immunol Res. 2024. PMID: 38314087 Free PMC article.
-
The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.Front Oncol. 2023 Oct 2;13:1240061. doi: 10.3389/fonc.2023.1240061. eCollection 2023. Front Oncol. 2023. PMID: 37849799 Free PMC article.
-
Antibody-Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives.J Pers Med. 2023 Aug 30;13(9):1339. doi: 10.3390/jpm13091339. J Pers Med. 2023. PMID: 37763107 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials